Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Louise Elkjær Fløe; Inge Marie Svane; Lars Bastholt; Henrik Schmidt

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Louise Elkjær Fløe, Inge Marie Svane, Lars Bastholt, Henrik Schmidt

Institut for Klinisk Medicin

2 Citationer (Scopus)

Abstract

The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

Bidragets oversatte titel	Immune checkpoint antibodies increase survival in patients with metastatic melanoma
Originalsprog	Dansk
Artikelnummer	V01160070
Tidsskrift	Ugeskrift for Laeger
Vol/bind	178
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

http://ugeskriftet.dk/videnskab/immuncheckpointantistoffer-oeger-overlevelsen-patienter-med-metastatisk-melanom

Citationsformater

@article{3fa8b083af994490bf5ea516165d0a85,

title = "Immuncheckpointantistoffer {\o}ger overlevelsen for patienter med metastatisk melanom",

abstract = "The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.",

keywords = "English Abstract, Journal Article",

author = "Fl{\o}e, {Louise Elkj{\ae}r} and Svane, {Inge Marie} and Lars Bastholt and Henrik Schmidt",

year = "2016",

language = "Dansk",

volume = "178",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

AU - Fløe, Louise Elkjær

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Schmidt, Henrik

PY - 2016

Y1 - 2016

N2 - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

AB - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 27550784

SN - 0041-5782

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V01160070

ER -

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater